Randox Covid-19 Testing: Evaluating the health, social and economic impacts

Home - National Testing Programme

Randox Covid-19 Testing: Evaluating the health, social and economic impacts

Randox Logo

   

3rd April 2023: COVID-19 Report Reveals How Randox’s 25 Million PCR Tests Averted Thousands of Hospitalisations and Deaths And Delivered Billions of Pounds Of Economic Benefits

A new report on the work of leading diagnostics company Randox shows that its COVID-19 PCR testing in the public and private sectors averted more than 3,000 UK deaths and 14,100 additional hospitalisations during the pandemic emergency.

That assessment is contained in an evidence-based report into the performance and delivery of Randox during the crisis, compiled by internationally respected economic development consultants OCO Global.

As well as illustrating the impact of PCR testing on deaths and hospitalisations, the report provides an assessment of the wider economic benefit of the test and trace programme.

It reveals that Randox testing delivered £8.3 billion of benefits to the UK economy, by reducing transmission and expediting the return to work for key workers, as well as facilitating social engagement and international travel, crucial to economic recovery.

The report is believed to be one of the most comprehensive analyses of any company awarded government Covid-19 contracts.  It will also be provided to the COVID-19 Public Inquiry to assist their considerations regarding future evidence that may be required.

In total, the OCO Global report confirms that Randox processed over 17 million PCR tests as part of the government’s national testing programme between March 2020 and June 2022. The company also provided a further 7.7 million PCR tests plus around 1.8 million lateral flow tests to corporate clients and international travelers.

The report estimates that Randox’s private testing facilitated 4.4 million international return journeys, many of them crucial to support the economy in a time of medical and financial emergency. Other tests supported the nation’s social fabric, enabling people to travel for leisure purposes and to meet families.

The evidence highlights the Northern Ireland-based company’s 40 years experience as one of the world’s leading diagnostic testing companies. This experience, says the OCO report, coupled with the company’s ability and willingness as a private business to innovate and invest its own resources in rapidly upscaling to meet the crisis enabled it successfully to deliver testing on a vast scale. The report also says that innovation in software, automation and robotics, in particular, helped ensure that Randox optimised laboratory efficiency and drove down costs to the benefit of contracting parties.

The report sets out the high level of financial risk taken by Randox during the pandemic and their rapid expansion of laboratories, staff levels and capacity to meet the emergency demand for testing.

In just ten months, Randox increased its capacity to process PCR tests – from 300 tests per day on March 30th 2020, to 120,000 per day by January 2021.

This involved building, equipping and staffing 80,000 square feet of PCR testing laboratory space at the Randox Science Park in County Antrim – the equivalent of a football pitch of new laboratory space.

Overall, the report confirms these improvements and development enabled Randox to deliver 12 per cent of the UK’s PCR testing – and a considerably higher percentage at times when Covid-19 cases, hospitalisations and deaths rocketed to their highest levels. It also notes that the Randox rate of void samples was 15 per cent below the average for the testing programme as a whole.

The report adds: “These improvements would be passed on to the UK Treasury as Randox was able to drive down the cost of testing from £49.60 to £18.00.

“Private individuals also benefited from Randox process improvement as the company was at the forefront of driving down the price of private testing. By October 2021 the cost of a PCR test (click and collect) would be £34.99, a 70 percent decrease from December 2020.”  This price included the sample collection kits and all logistics and services, not within the government contracts.

In assessing Randox’s performance the report goes on to say:  “Randox is a privately owned company that can make decisions quickly and this proved invaluable in the frenetic early stages of the pandemic when companies and governments across the world were scrambling for supplies and consumables.

“Randox’s willingness to invest came with significant risk: through the majority of the National Testing Programme, Randox were only paid for tests completed and there were no guarantees that payment for the number of tests indicatively contracted for would be received.

“This placed considerable risk with Randox who were having to purchase vast quantities of consumables, despite the uncertainty around how long the pandemic would last or how government policy might change.

“It was this successful risk management which enabled Randox to be one of the best performing laboratories across the National Testing Programme.”

Gareth Hagan, CEO of OCO Global said:

“OCO Global was commissioned by Randox to compile a full, open and comprehensive report into the value of the company’s work, performance and delivery of PCR testing during the pandemic. Randox was a cooperative partner, providing access both to data and to personnel from across the organisation.

“We were able to use external interviews and data sources to corroborate our research. We are satisfied that the facts and the evidence-based findings of our report accurately reflect the work of Randox  during the Covid-19 emergency.”

A spokesman for Randox said:

“We believe this report delivers clear evidence of the performance, outcomes and value of the work which Randox is proud to have carried out during one of the greatest peacetime emergencies to have hit the world and the UK.

Editors Notes

Gareth Hagan is interview for media interview

OCO Global is a leading specialist provider of trade and investment services. Headquartered in Northern Ireland, OCO Global has offices in the UK, Ireland, Germany, France, Japan, UAE, China and the U.S.

OCO Global’s clients include leading national, state and regional economic development organizations such as The Department For International Trade (DIT), Enterprise Florida and The Japan External Trade Organization (JETRO), as well as private companies seeking to enter new markets or grow their domestic base, including EY, PWC, Siemens, Smiley Monroe, Pepsico and Santander.

Media Enquiries to Ian Monk /Heather Vernon

Ian.monk@woburnpartners.com                  +44 7970 026072

Heather.vernon@woburnpartners.com      +44 7747 097821

Randox in the media

Latest News

FAQs


Randox response to the Public Accounts Committee (PAC) report, ‘Government’s contracts with Randox Laboratories Ltd’

Randox Logo

   

27th July 2022: Randox response to the Public Accounts Committee (PAC) report, ‘Government’s contracts with Randox Laboratories Ltd’

A spokesperson for Randox said:

“The PAC report is deeply flawed and wrong in assumptions it makes and the conclusions it draws about Randox.

“As the UK’s largest diagnostic company, with four decades of experience, over 2,000 professional staff on hand at the start of the pandemic and more than £350m of prior investment in diagnostic and engineering innovation, Randox was uniquely situated to respond to the national need when COVID-19 emerged in early 2020.

“In supporting the UK’s urgent requirement for coronavirus testing Randox reacted with speed, efficiency and flexibility in delivering value. The company developed and built, in record time, the UK’s largest COVID-19 laboratories and testing services. It provided the Department of Health and Social Care with a PCR testing capacity at the time of greatest need, rising from 300 tests per day to 120,000 per day by January 2021.

“Altogether Randox processed over 25 million samples for UK’s National Testing Programme and in support of international travel for business and personal reasons. This played a crucial role in keeping vital elements of the UK economy functioning during lockdowns.

“In adapting to rapidly changing DHSC and Department of Transport requirements, Randox delivered unique value to the government, the national economy and to individuals.

“At no stage, either during its deliberations or in its preparation of this report, did the PAC make any contact whatsoever with Randox. Consequently many elements of its report relating to Randox are false, based as they are, on wrong and unchecked assumptions about the company. For that reason, they and any publications arising from them are the subject of a legal complaint.”

“The issues the report raises around internal DHSC record keeping are clearly a matter for DHSC”

For all media enquiries, please contact Ian Monk on ian@ianmonk.com or  +44 7970 026072 / + 44 203 011 1933

 

Randox in the media

Latest News

FAQs


Response to release of specified minutes, notes and correspondence relating to Government contracts awarded to Randox

Randox Logo

   

4th February 2022: Response to release of specified minutes, notes and correspondence relating to Government contracts awarded to Randox

A spokesperson for Randox said:

“It is clear from these papers that Randox contracts were awarded in full compliance with government procedures and protocols in place at a time of the emerging pandemic.

“The awarding of the contracts reflected Randox’s extensive diagnostics capabilities within the UK and 40 years of experience in that field. As Secretary of State, Sajid Javid says in his statement, the service Randox provided was integral to the rapid building, from scratch, of the largest ever testing industry in UK history.

“Randox’s laboratories expanded rapidly in order to operate at scale and were the first laboratory to report over 100,000 PCR results in a day. It is clear from these papers that the company has delivered a vital and core part of the UK’s testing capacity.

“Randox remains proud of its performance and delivery of Covid 19 testing throughout the pandemic. To date Randox has reported almost 24 million PCR results and has played a key role in both keeping people safe and sustaining vital national infrastructure.

“Unlike other laboratories Randox was able from the outset to provide whole-system capabilities to deliver the tests. Both the World Health Organisation and the UK government agreed this capability was crucial to combating the pandemic.”

For all media enquiries, please contact Ian Monk on ian@ianmonk.com or  +44 7970 026072 / + 44 203 011 1933

Randox in the media

Latest News

FAQs


Ministers and MPs Praise Randox’s ‘Life-Saving’ Role In Delivering Mass Testing During Pandemic

Randox Logo

   

18th November 2021

Speaking in the House of Commons on behalf of the government on November 17, Health Minister Gillian Keegan praised Randox’s 40 years of experience in testing and diagnostics. She confirmed to the House that as early as March 2020, Randox already had lab-based PCR testing capacity for Covid-19.

Recognising the imperative of testing as a weapon against the pandemic and facing a shortage of proven testing capacity, she said “the Government had made the common sense decision to work with companies that had existing diagnostic capability.”

The Minister continued: “The initial challenge that (Randox) faced was the challenge facing governments the world over: a shortage of machinery and transport. Nonetheless, it quickly overcame them to play a critical role in our pandemic response.”

She also confirmed that in June 2020, Randox was ahead of all other labs in process, plans, and reporting. A six-month-extension was agreed in September 2020, and by March 2021 Randox was exceeding contract targets, processing more than 120,000 tests in a single day.

Keegan said to date, that Randox has carried out over 15 million tests for Covid-19, and identified over 700,000 positive cases. “That is 700,000 people who might otherwise have gone on to spread the disease,” She continued: “As a result of this testing capacity, they received the right advice to isolate, thereby protecting their friends, their family and society at large.”

Her recognition of Randox’s crucial role in combatting the pandemic at its height was echoed by Maggie Throup MP, Minister for Vaccines and Public Health, who said that working with Randox was a decision which had “saved many thousands of lives”.

She told the House: “contracts with companies such as Randox have been some of the essential building blocks without which we would never have built what is now one of the largest testing networks in the world.”

Throup said she “utterly rejected” the idea that Randox had received any kind of special treatment.

“Our partnership with Randox is simply a reflection of the situation in which we found ourselves in March 2020”, she clarified, “facing a global pandemic of unknown and unprecedented proportions and acting as a responsible Government should. We worked against genuine fears that we would run out of vital testing equipment, that we would not have the capacity to test people and that the deadly virus might continue to spread from person to person, silent and undetected.” 

“Working with Randox was the right thing to do, it was the responsible thing to do and, quite simply, it was a decision that has saved many thousands of lives”, she told MPs.

 

For all media enquiries, please contact Ian Monk on ian@ianmonk.com or  +44 7970 026072 / + 44 203 011 1933

Randox in the media

Latest News

FAQs


House of Commons Debate | Randox Statement

Randox Logo

   

17th November 2021: House of Commons Debate | Randox Statement

Randox will be pleased to co-operate fully in laying before the House all the material required.

Public disclosure will demonstrate the extraordinary efficiency and value for money provided by Randox through contracts awarded in full compliance with government regulations at a time of national crisis.

Contrary to much of what has been written and broadcast, lobbying played no role in the awarding of these contracts.

The company has 40 years experience in testing and diagnostics. It is proud of its performance and delivery under the contracts awarded to it on merit by the Government. They resulted in the delivery of more than 21 million Covid tests, 15 million of them to the National Testing Programme from the start of the emergency in the Spring of 2020.

At this time, hindered by global shortages and less experience than Randox, other laboratories were simply not able to provide whole-system capabilities to deliver the tests which the World Health Organisation and the UK government agreed were crucial to combating the pandemic.

 

11th November 2021: COVID Contracts | Randox Statement

Randox  states categorically that political lobbying played no role in the award of Covid contracts to the company. The Department of Health and Social Care (DHSC) contracts to provide Covid-19 testing were awarded on merit to Randox as the largest healthcare diagnostic company from the UK. The entire process was transparent and compliant with government regulations in a time of national crisis.

Randox has almost 40 years experience in testing and diagnostics: it was one of the first companies in the world to develop a Covid-19 test and to have developed extensive laboratory, IT and logistic infrastructure to support large scale testing operations. The decision to award Covid-19 contracts was fully validated by the company’s performance and delivery under the terms of the contracts.

The company was awarded its initial Covid contract on 30 Mar 20 and, within a short period, had exceeded the initial Covid-19 testing capability of the entire NHS.

Subsequent DHSC planning required Randox to deliver 17,000 tests per day by the end of April and more beyond then. To facilitate and ultimately enable these extraordinary levels of delivery, Randox was temporarily allocated 5 extraction systems from universities in order to increase capacity. DHSC directed the Army to collect equipment, in line with their support for all Pillar 2 laboratories.

This was a pragmatic and transparent move by the DHSC to meet a critical national need to save lives and ease overwhelming pressure on the NHS.  The extraction systems were returned once the systems ordered by Randox, against the backdrop of a global shortage of such equipment, had been delivered and installed.

Randox and its staff have striven tirelessly and innovatively to support the national Covid-19 testing effort. We are proud of our collective achievement at a time of crisis in being the only Pillar 2 laboratory to have reported in excess of 100,000 Covid-19 results in one day.

 

For all media enquiries, please contact Ian Monk on ian@ianmonk.com or  +44 7970 026072 / + 44 203 011 1933

 

Randox in the media

Latest News

FAQs


COVID Contracts | Randox Statement

Randox Logo

   

11th November 2021: COVID Contracts | Randox Statement

Randox  states categorically that political lobbying played no role in the award of Covid contracts to the company. The Department of Health and Social Care (DHSC) contracts to provide Covid-19 testing were awarded on merit to Randox as the largest healthcare diagnostic company from the UK. The entire process was transparent and compliant with government regulations in a time of national crisis.

Randox has almost 40 years experience in testing and diagnostics: it was one of the first companies in the world to develop a Covid-19 test and to have developed extensive laboratory, IT and logistic infrastructure to support large scale testing operations. The decision to award Covid-19 contracts was fully validated by the company’s performance and delivery under the terms of the contracts.

The company was awarded its initial Covid contract on 30 Mar 20 and, within a short period, had exceeded the initial Covid-19 testing capability of the entire NHS.

Subsequent DHSC planning required Randox to deliver 17,000 tests per day by the end of April and more beyond then. To facilitate and ultimately enable these extraordinary levels of delivery, Randox was temporarily allocated 5 extraction systems from universities in order to increase capacity. DHSC directed the Army to collect equipment, in line with their support for all Pillar 2 laboratories.

This was a pragmatic and transparent move by the DHSC to meet a critical national need to save lives and ease overwhelming pressure on the NHS.  The extraction systems were returned once the systems ordered by Randox, against the backdrop of a global shortage of such equipment, had been delivered and installed.

Randox and its staff have striven tirelessly and innovatively to support the national Covid-19 testing effort. We are proud of our collective achievement at a time of crisis in being the only Pillar 2 laboratory to have reported in excess of 100,000 Covid-19 results in one day.

 

For all media enquiries, please contact Ian Monk on ian@ianmonk.com or  +44 7970 026072 / + 44 203 011 1933

Randox in the media

Latest News

FAQs


23rd October 2021: 20 million tests across the National Testing Programme and testing for travel

Randox Logo

   

23RD OCTOBER 2021: THE 20 MILLION MILESTONE 

We are pleased to let you know that on 23rd October 2021, Randox processed its 20 millionth across the UK COVID-19 National Testing Programme and testing for international travel.

That’s an incredible 20 million samples processed by our dedicated and talented staff.

Our staff are our best asset and have risen to the challenge this pandemic has created.

They have worked hard and flexibly, been creative and innovative, and pulled together as a team to make an impact in the fight against COVID-19.

We are very proud of their efforts and teamwork.

Let us once again say thank you to each and every member of Team Randox, for the efforts they have made.

What we do at Randox remains vital to the national and global management of COVID-19 and our work is making a real and positive difference.

We continue to work hard and improve, for the sake of our family, friends and communities.

For further information please email randoxpr@randox.com

Randox in the media

Latest News

FAQs


15th May 2021: 13 million tests on the National Testing Programme

Randox Logo

   

15TH MAY 2021: THE 13 MILLION MILESTONE 

We are pleased to let you know that on 15th May 2021, Randox processed its 13 millionth sample within the UK COVID-19 National Testing Programme.

That’s an incredible 13 million samples processed by our dedicated and talented staff.

Our staff are our best asset and have risen to the challenge this pandemic has created.

They have worked hard and flexibly, been creative and innovative, and pulled together as a team to make an impact in the fight against COVID-19.

We are very proud of their efforts and teamwork.

Let us once again say thank you to each and every member of Team Randox, for the efforts they have made.

What we do at Randox remains vital to the national and global management of COVID-19 and our work is making a real and positive difference.

We continue to work hard and improve, for the sake of our family, friends and communities.

For further information please email randoxpr@randox.com

Randox in the media

Latest News

FAQs


9th April 2021: 12 million tests on the National Testing Programme

Randox Logo

   

09TH APRIL 2021: THE 12 MILLION MILESTONE 

We are pleased to let you know that on 09th April 2021, Randox processed its 12 millionth sample within the UK COVID-19 National Testing Programme.

That’s an incredible 12 million samples processed by our dedicated and talented staff.

Our staff are our best asset and have risen to the challenge this pandemic has created.

They have worked hard and flexibly, been creative and innovative, and pulled together as a team to make an impact in the fight against COVID-19.

We are very proud of their efforts and teamwork.

Let us once again say thank you to each and every member of Team Randox, for the efforts they have made.

What we do at Randox remains vital to the national and global management of COVID-19 and our work is making a real and positive difference.

We continue to work hard and improve, for the sake of our family, friends and communities.

For further information please email randoxpr@randox.com

Randox in the media

Latest News

FAQs


11th March 2021: 11 million tests on the National Testing Programme

Randox Logo

   

11TH MARCH 2021: THE 11 MILLION MILESTONE 

We are pleased to let you know that on 11th March 2021, Randox processed its 11 millionth sample within the UK COVID-19 National Testing Programme.

That’s an incredible 11 million samples processed by our dedicated and talented staff.

Our staff are our best asset and have risen to the challenge this pandemic has created.

They have worked hard and flexibly, been creative and innovative, and pulled together as a team to make an impact in the fight against COVID-19.

We are very proud of their efforts and teamwork.

Let us once again say thank you to each and every member of Team Randox, for the efforts they have made.

What we do at Randox remains vital to the national and global management of COVID-19 and our work is making a real and positive difference.

We continue to work hard and improve, for the sake of our family, friends and communities.

For further information please email randoxpr@randox.com

Randox in the media

Latest News

FAQs


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.